ZX008 (Fenfluramine Hydrochloride) is an oral solution used as an additional treatment for seizures. It is specifically aimed at helping patients with rare seizure disorders, including conditions like Dravet Syndrome and Lennox-Gastaut Syndrome. The purpose of using this medication in the trial is to evaluate its long-term safety and how well patients can tolerate it when used alongside their existing seizure treatments.

Dravet Syndrome – Dravet syndrome is a rare, severe form of epilepsy that begins in infancy. It is characterized by prolonged seizures that are often triggered by fever or hot temperatures. As the child grows, other types of seizures may develop, including myoclonic and absence seizures. The condition can also lead to developmental delays, speech impairment, and motor difficulties. Children with Dravet syndrome may experience behavioral challenges and have an increased risk of sudden unexplained death in epilepsy (SUDEP). The syndrome is often associated with a genetic mutation in the SCN1A gene.

Lennox-Gastaut Syndrome – Lennox-Gastaut syndrome is a complex, rare form of epilepsy that typically begins in early childhood. It is characterized by multiple types of seizures, including tonic, atonic, and atypical absence seizures. The condition often leads to developmental delays and cognitive impairment. Children with Lennox-Gastaut syndrome may also experience behavioral problems and difficulties with coordination. The seizures are usually resistant to standard epilepsy treatments, making management challenging. The cause of Lennox-Gastaut syndrome can vary, including brain malformations, genetic disorders, or unknown factors.